Biphasic function of GSK3β in gefitinib‑resistant NSCLC with or without EGFR mutations

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, are effective in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, the mechanism underlying acquired resistance to EGFR-TKIs remains largely unknown. Therefore, the presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junzhe, Wu, Xiayu, Ji, Xiang-Bo, He, Changhao, Xu, Shijie, Xu, Xianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515113/
https://www.ncbi.nlm.nih.gov/pubmed/37745038
http://dx.doi.org/10.3892/etm.2023.12187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515113/
https://www.ncbi.nlm.nih.gov/pubmed/37745038
http://dx.doi.org/10.3892/etm.2023.12187

Ejemplares similares